X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9137) 9137
Publication (929) 929
Newsletter (495) 495
Book Review (66) 66
Dissertation (30) 30
Book Chapter (25) 25
Newspaper Article (13) 13
Conference Proceeding (10) 10
Magazine Article (5) 5
Reference (2) 2
Trade Publication Article (2) 2
Book / eBook (1) 1
Data Set (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
gefitinib (8723) 8723
humans (6140) 6140
oncology (5248) 5248
index medicus (5191) 5191
female (3237) 3237
lung neoplasms - drug therapy (2903) 2903
mutation (2903) 2903
male (2897) 2897
erlotinib (2894) 2894
cancer (2877) 2877
chemotherapy (2817) 2817
lung cancer (2611) 2611
middle aged (2544) 2544
aged (2436) 2436
carcinoma, non-small-cell lung - drug therapy (2389) 2389
lung neoplasms - genetics (2359) 2359
lung cancer, non-small cell (2302) 2302
receptor, epidermal growth factor - genetics (2076) 2076
epidermal growth factor (2043) 2043
lung neoplasms - pathology (1969) 1969
egfr (1943) 1943
adult (1776) 1776
carcinoma, non-small-cell lung - genetics (1699) 1699
care and treatment (1689) 1689
receptor, epidermal growth factor - antagonists & inhibitors (1580) 1580
antineoplastic agents - therapeutic use (1578) 1578
growth-factor receptor (1571) 1571
cell lung-cancer (1560) 1560
adenocarcinoma (1558) 1558
mutations (1447) 1447
quinazolines - therapeutic use (1430) 1430
research (1429) 1429
non-small cell lung cancer (1398) 1398
genetic aspects (1363) 1363
carcinoma, non-small-cell lung - pathology (1361) 1361
respiratory system (1335) 1335
protein kinase inhibitors - therapeutic use (1286) 1286
aged, 80 and over (1274) 1274
cell line, tumor (1254) 1254
tumors (1201) 1201
treatment outcome (1172) 1172
therapy (1132) 1132
epidermal growth factor receptor (1121) 1121
tyrosine (1121) 1121
open-label (1102) 1102
acquired-resistance (1098) 1098
respiratory tract diseases (1060) 1060
tyrosine kinase inhibitors (1036) 1036
analysis (1035) 1035
tyrosine kinase inhibitor (1018) 1018
prognosis (988) 988
quinazolines - pharmacology (982) 982
survival (979) 979
animals (976) 976
kinases (951) 951
antineoplastic agents - pharmacology (948) 948
receptor, epidermal growth factor - metabolism (935) 935
expression (896) 896
erlotinib hydrochloride (868) 868
resistance (867) 867
cancer therapies (849) 849
egfr mutations (826) 826
1st-line treatment (813) 813
metastasis (795) 795
protein kinase inhibitors - pharmacology (791) 791
health aspects (788) 788
nsclc (779) 779
pharmacology & pharmacy (768) 768
adenocarcinoma - genetics (763) 763
neoplasm staging (756) 756
lung neoplasms - mortality (747) 747
epidermal growth factor receptors (731) 731
lung neoplasms - metabolism (709) 709
hematology, oncology and palliative medicine (707) 707
apoptosis (684) 684
quinazolines - administration & dosage (684) 684
disease-free survival (662) 662
adenocarcinoma - drug therapy (660) 660
antineoplastic combined chemotherapy protocols - therapeutic use (660) 660
growth-factor-receptor (657) 657
lung-cancer (656) 656
mice (649) 649
drug therapy (642) 642
trial (640) 640
retrospective studies (639) 639
patients (623) 623
egfr mutation (622) 622
carcinoma, non-small-cell lung - mortality (612) 612
sensitivity (589) 589
cell biology (579) 579
erbb receptors - genetics (573) 573
adenocarcinoma - pathology (558) 558
medicine & public health (553) 553
non-small-cell lung cancer (550) 550
multicenter (548) 548
development and progression (543) 543
drug resistance, neoplasm (543) 543
non-small cell lung carcinoma (535) 535
carcinoma (526) 526
quinazolines - adverse effects (525) 525
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9476) 9476
French (73) 73
Chinese (41) 41
Korean (28) 28
Japanese (25) 25
German (20) 20
Spanish (11) 11
Polish (4) 4
Portuguese (3) 3
Czech (2) 2
Russian (2) 2
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


NATURE, ISSN 0028-0836, 09/2014, Volume 513, Issue 7517, pp. S8 - S9
Journal Article
The Lancet Oncology, ISSN 1470-2045, 01/2018, Volume 19, Issue 1, pp. 139 - 148
Cisplatin-based adjuvant chemotherapy is the standard of care for patients with resected stage II–IIIA non-small-cell lung cancer (NSCLC). RADIANT and SELECT... 
CELL LUNG-CANCER | SURVIVAL | FORTHCOMING 7TH EDITION | 1ST-LINE TREATMENT | PLACEBO | ESMO CONSENSUS CONFERENCE | THERAPY | ONCOLOGY | TNM CLASSIFICATION | ERLOTINIB | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | ErbB Receptors - genetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Pneumonectomy | Protein Kinase Inhibitors - adverse effects | Vinblastine - administration & dosage | Cisplatin - administration & dosage | Young Adult | Time Factors | Vinblastine - analogs & derivatives | Vinblastine - adverse effects | China | Adult | Female | Quinazolines - administration & dosage | Chemotherapy, Adjuvant | Gefitinib | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Risk Factors | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Disease Progression | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Quinazolines - adverse effects | Cisplatin - adverse effects | Aged | Biomarkers, Tumor - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Neoplasm Staging | Vinorelbine | Lung cancer, Non-small cell | Care and treatment
Journal Article
The Lancet Oncology, ISSN 1470-2045, 11/2017, Volume 18, Issue 11, pp. 1454 - 1466
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2018, Volume 36, Issue 9, pp. 841 - 849
Purpose The AURA study (ClinicalTrials.gov identifier: NCT01802632) included two cohorts of treatment-naive patients to examine clinical activity and safety of... 
TYROSINE KINASE INHIBITORS | SURVIVAL | MULTICENTER | GEFITINIB | THERAPY | ONCOLOGY | ACQUIRED-RESISTANCE | OPEN-LABEL | AFATINIB | AZD9291 | ERLOTINIB
Journal Article
NEW ENGLAND JOURNAL OF MEDICINE, ISSN 0028-4793, 09/2009, Volume 361, Issue 12, pp. 1173 - 1178
Medulloblastoma is the most common malignant brain tumor in children. Aberrant activation of the hedgehog signaling pathway is strongly implicated in the... 
CELL LUNG-CANCER | MEDICINE, GENERAL & INTERNAL | GEFITINIB | SONIC HEDGEHOG | STAGE | IMATINIB | TUMOR | RESISTANCE | MICE | MUTATIONS | CHRONIC MYELOID-LEUKEMIA
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 7, pp. 619 - 626
Journal Article
Cancer Discovery, ISSN 2159-8274, 09/2011, Volume 1, Issue 4, pp. 352 - 365
Cancers with specific genetic mutations are susceptible to selective kinase inhibitors. However, there is a wide spectrum of benefit among cancers harboring... 
CELL LUNG-CANCER | BREAST-CANCER | GEFITINIB | ACTIVATION | GROWTH-FACTOR-RECEPTOR | MET AMPLIFICATION | ONCOLOGY | INDUCED APOPTOSIS | PHASE-II | MUTATIONS | EGFR | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Receptor, ErbB-2 - genetics | Apoptosis - drug effects | Humans | Lung Neoplasms - metabolism | Receptor, ErbB-2 - metabolism | Apoptosis - genetics | BH3 Interacting Domain Death Agonist Protein - genetics | Phosphatidylinositol 3-Kinases - metabolism | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Proto-Oncogene Proteins - biosynthesis | Receptor, Epidermal Growth Factor - metabolism | Bcl-2-Like Protein 11 | Apoptosis Regulatory Proteins - genetics | Female | Membrane Proteins - metabolism | Receptor, ErbB-2 - antagonists & inhibitors | Retrospective Studies | BH3 Interacting Domain Death Agonist Protein - metabolism | Oncogenes | Apoptosis Regulatory Proteins - biosynthesis | Lung Neoplasms - genetics | Proto-Oncogene Proteins - metabolism | Membrane Proteins - genetics | Proto-Oncogene Proteins - genetics | Apoptosis Regulatory Proteins - metabolism | Phosphatidylinositol 3-Kinases - genetics | Membrane Proteins - biosynthesis | Animals | Signal Transduction - drug effects | Mice, Nude | Cell Line, Tumor | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Mice | Protein Kinase Inhibitors - pharmacology | Cohort Studies | oncogene addiction | apoptosis | HER2 | BIM
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 5, pp. 577 - 589
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 2, pp. 213 - 222
Summary Background Afatinib—an oral irreversible ErbB family blocker—improves progression-free survival compared with pemetrexed and cisplatin for first-line... 
Hematology, Oncology and Palliative Medicine | GEFITINIB | MULTICENTER | SOLID TUMORS | ONCOLOGY | ADENOCARCINOMA | CLINICAL-TRIALS | INHIBITOR | ERBB FAMILY BLOCKER | CHEMOTHERAPY | ERLOTINIB | Lung Neoplasms - drug therapy | Lung Neoplasms - ethnology | Receptor, Epidermal Growth Factor - genetics | Lung Neoplasms - mortality | Humans | Middle Aged | Thailand - epidemiology | Asian Continental Ancestry Group - genetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Protein Kinase Inhibitors - adverse effects | Cisplatin - administration & dosage | Time Factors | Female | Odds Ratio | Republic of Korea - epidemiology | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Deoxycytidine - administration & dosage | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Carcinoma, Non-Small-Cell Lung - ethnology | Linear Models | Logistic Models | Treatment Outcome | China - epidemiology | Carcinoma, Non-Small-Cell Lung - mortality | Disease Progression | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Intention to Treat Analysis | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Neoplasm Staging | Deoxycytidine - analogs & derivatives | Antimitotic agents | Medical colleges | Care and treatment | Chemotherapy | Product development | Lung cancer, Non-small cell | Antineoplastic agents | Tumors | Cancer | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2011, Volume 29, Issue 8, pp. 1067 - 1074
Journal Article
Cancer, ISSN 0008-543X, 12/2012, Volume 118, Issue 24, pp. 6234 - 6242
Journal Article
by Rosell, Rafael, Dr and Carcereny, Enric, MD and Gervais, Radj, MD and Vergnenegre, Alain, Prof and Massuti, Bartomeu, MD and Felip, Enriqueta, MD and Palmero, Ramon, MD and Garcia-Gomez, Ramon, MD and Pallares, Cinta, MD and Sanchez, Jose Miguel, MD and Porta, Rut, MD and Cobo, Manuel, MD and Garrido, Pilar, MD and Longo, Flavia, MD and Moran, Teresa, MD and Insa, Amelia, MD and De Marinis, Filippo, MD and Corre, Romain, MD and Bover, Isabel, MD and Illiano, Alfonso, MD and Dansin, Eric, MD and de Castro, Javier, MD and Milella, Michele, MD and Reguart, Noemi, MD and Altavilla, Giuseppe, MD and Jimenez, Ulpiano, MD and Provencio, Mariano, MD and Moreno, Miguel Angel, MD and Terrasa, Josefa, MD and Muñoz-Langa, Jose, MD and Valdivia, Javier, MD and Isla, Dolores, MD and Domine, Manuel, MD and Molinier, Olivier, MD and Mazieres, Julien, Prof and Baize, Nathalie, MD and Garcia-Campelo, Rosario, MD and Robinet, Gilles, MD and Rodriguez-Abreu, Delvys, MD and Lopez-Vivanco, Guillermo, MD and Gebbia, Vittorio, MD and Ferrera-Delgado, Lioba, MD and Bombaron, Pierre, MD and Bernabe, Reyes, MD and Bearz, Alessandra, MD and Artal, Angel, MD and Cortesi, Enrico, MD and Rolfo, Christian, MD and Sanchez-Ronco, Maria, PhD and Drozdowskyj, Ana, PhD and Queralt, Cristina, PhD and de Aguirre, Itziar, PhD and Ramirez, Jose Luis, PhD and Sanchez, Jose Javier, Prof and Molina, Miguel Angel, PhD and Taron, Miquel, PhD and Paz-Ares, Luis, MD and Assoc Italiana Oncologia Toracica and Grp Francais Pneumocancerologie and Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 3, pp. 239 - 246
Summary Background Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian... 
Hematology, Oncology and Palliative Medicine | IPASS | GEFITINIB | THERAPY | ONCOLOGY | SENSITIVITY | CARBOPLATIN/PACLITAXEL | TUMORS | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Prospective Studies | Exons | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Cisplatin - administration & dosage | Patient Selection | Time Factors | Female | Quinazolines - administration & dosage | Precision Medicine | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Lung Neoplasms - enzymology | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Deoxycytidine - administration & dosage | Europe | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Deoxycytidine - analogs & derivatives | Antimitotic agents | Care and treatment | Chemotherapy | Erlotinib | Lung cancer | Product development | Agriculture | Lung cancer, Non-small cell | Antineoplastic agents | Standards | Cancer
Journal Article